Issue Archive
December 2008 | Volume 7 | Issue 12
Original Articles
Phase 4 Study to Assess Tretinoin Pump for the Treatment of Facial Acne
It is well known that the setting of clinical trials for registration studies do not necessarily represent efficacy seen in clinical practice, where physicians have the flexibility to se...
Read MoreAdverse Drug Events in Infliximab-treated Patients Compared With the General and Psoriasis Populations
Introduction: Infliximab is indicated for severe plaque psoriasis (PsO). The investigators compared safety event rates in infliximab PsO trials with those of the general United States an...
Read MoreSubantimicrobial-dose Doxycycline in the Treatment of Moderate Facial Acne
Background: Acne is a common inflammatory skin disorder. Oral antibiotics play a significant clinical role in treating acne.
Objective: The purpose of this study was to compare th...
Read MoreAdult Patients With Moderate Atopic Dermatitis: Tacrolimus Ointment Versus Pimecrolimus Cream
The objective of this study was to compare the effi cacy and safety of tacrolimus ointment and pimecrolimus cream in adults with moderate atopic dermatitis (AD). A randomized, investigator-bli...
Read MorePipeline Previews
Case Reports
Dimorphic Cutaneous Manifestation of a Toxic Eruption Due to Erlotinib Therapy
The epidermal growth factor receptor (EGFR) inhibitor class of agents have been reported to cause multiple cutaneous adverse events. These drug eruptions are thought by some to indicate a good progn...
Read MoreTreatment of Severe Facial Psoriasis With Adalimumab
Background: Psoriasis of the skin is in itself a disturbing disorder both physically and psychologically. However, most often the scaly plaques can be hidden by clothing. When psoriasis involves the...
Read MoreA Ribose-crosslinked Collagen Filler Treatment for Facial Lipoatrophy Associated With the Treatment of Human Immunodeficiency Virus
Background: Facial lipoatrophy is a common problem for patients with human immunodefi ciency virus (HIV) treated with highly active antiretroviral therapy (HAART). The loss of subcutaneous fac...
Read More
